SCHEMBL22952987

SCHEMBL22952987

COc1cc(OC)c2c3c1CNCC3c1ccc(O)c(O)c1C2

nearest known ligand 0.55

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PARP1 P09874 1/20 0.41
DRD1 P21728 4/20 0.41
DRD5 P21918 4/20 0.41
CHRNB2 P17787 1/20 0.35
CHRNA4 P43681 1/20 0.35
CETP P11597 1/20 0.34
LMNA P02545 2/20 0.33
KDM4E B2RXH2 1/20 0.33
ALDH1A1 P00352 1/20 0.33
TP53 P04637 1/20 0.33
CYP3A4 P08684 1/20 0.33
MAPT P10636 1/20 0.33
HPGD P15428 1/20 0.33
ALOX15 P16050 1/20 0.33
ALOX12 P18054 1/20 0.33
MAPK1 P28482 1/20 0.33
HSD17B10 Q99714 1/20 0.33
HTR2A P28223 2/20 0.33
HTR2C P28335 1/20 0.33
KIF11 P52732 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL22953344 0.80 PARP1 (0.39) PARP1DRD1DRD5CHRNB2CHRNA4
SCHEMBL22952989 0.80 PARP1 (0.43) PARP1LMNAKDM4EALDH1A1CYP3A4
SCHEMBL22953386 0.76 PARP1 (0.39) PARP1LMNAHTR2AKIF11
SCHEMBL22952986 0.76 PARP1 (0.46) PARP1DRD1LMNAKDM4EALDH1A1
SCHEMBL22953389 0.74 HTR2A (0.34) PARP1DRD1DRD5HTR2A
SCHEMBL16938669 0.71 HTR2A (0.60) PARP1DRD1DRD5CYP3A4HTR2A
SCHEMBL29383346 0.71 HTR2A (0.60) PARP1DRD1DRD5CYP3A4HTR2A
SCHEMBL3670524 0.71 HTR2A (0.60) PARP1DRD1DRD5CYP3A4HTR2A
SCHEMBL3672464 0.71 HTR2A (0.60) PARP1DRD1DRD5CYP3A4HTR2A
SCHEMBL22953390 0.70 HTR2A (0.36) PARP1DRD1HTR2AKIF11

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2021021922-A1 COMPOUNDS AND METHODS FOR TREATING FIBROTIC PATHOLOGIES MAYO FOUNDATION FOR MEDICAL EDUCATION AND RESEARCH (US) 2021-02-04 WO disclosed